<span>Generation of polyclonal anti-idiotype antibodies</span>
December 14, 2023

Generation of polyclonal anti-idiotype antibodies

An idiotype is a unique antigen-binding site in an antibody and is made up of several epitopes in the variable region. Antibodies raised against the idiotype of a given antibody are called anti-idiotypic antibodies or commonly anti-Ids. These anti-Ids are highly specialized reagents that are produced against human monoclonal antibody (mAb) drug therapeutics. Anti-Id antibodies are generally used for the detection, identification and analysis of therapeutic drugs or as a positive control in immunogenicity assays to support preclinical and clinical development.
<span>Biomarker Q&A: The landscape and outlook for precision medicine in neurology</span>
January 27, 2023

Biomarker Q&A: The landscape and outlook for precision medicine in neurology

Labcorp Drug Development has continued to invest in the technology, innovation and expertise globally to support clients focused on bringing life-changing treatments to patients with neurological diseases. We recently spoke with Robert Martone, Associate Director, Neurology Biomarkers with the Biomarker Solution Center, to learn about the acceleration and expansion of biomarkers and diagnostic development related to neurological disease.
February 23, 2024

Central lab capabilities in Japan: Insights from a recent symposium

In this video, Catherine Ohura, VP and general manager at Labcorp laboratories in Japan, alongside Takashi Shibata, site lead for Labcorp Central Laboratories in Japan, provide an overview of Labcorp’s central lab capabilities in Japan. Additionally, Kazuya Kurachi, senior director of global regulatory operations, discusses CDx development in Japan. Discussing the lab’s significant expansions over the years, they detail its steady growth in capabilities. Through a collaboration with BML, the lab is set to grow even further by 2025. The facility’s expanded offerings will include flow cytometry, immunology, and anatomic pathology and histology.
February 12, 2024

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

This study reports a prespecified exploratory biomarker analysis of the Phase III PARAGIGM trial, which demonstrated increased overall survival with first-line anti-EGFR (panitumumab) therapy as compared with anti-vascular endothelial growth factor (bevacizumab) therapy in combination with modified FOLFOX6 in RAS wild-type metastatic colorectal cancer patient

February 21, 2024

Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles

Despite the diagnostic contribution of Anti-CCP 3.1 (cyclic citrullinated peptide) antibody and RF (rheumatoid factor) as classified by the 2010 ACR/EULAR RA criteria, approximately one-third of patients with rheumatoid arthritis (RA) are considered “seronegative.” Novel markers, Anti-CarP Anti-Sa, and Anti-CEP-1 were recently added in order to improve RA diagnosis and characterization. These autoantibodies may predict the development of RA and may be associated with more active disease and higher risk of developing joint erosions.